In the literature some evidence is present in relation to RXRα [19] and PPARγ [20] genes mutations in bladder cancer that can cause PPARs/RXRα pathway hyperactivation resulting in the cellular proliferation, even though they were not related to ATRA treatments. The gene discussed is RXRA; the disease is urinary bladder carcinoma.